Literature DB >> 27626519

Biologic and Clinical Perspectives on Thyroid Cancer.

James A Fagin1, Samuel A Wells1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27626519      PMCID： PMC5512163          DOI： 10.1056/NEJMra1501993

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  88 in total

1.  Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells.

Authors:  M N Nikiforova; J R Stringer; R Blough; M Medvedovic; J A Fagin; Y E Nikiforov
Journal:  Science       Date:  2000-10-06       Impact factor: 47.728

2.  Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation.

Authors:  Sina Jasim; Anita K Ying; Steven G Waguespack; Thereasa A Rich; Elizabeth G Grubbs; Camilo Jimenez; Mimi I Hu; Gilbert Cote; Mouhammed Amir Habra
Journal:  Thyroid       Date:  2010-12-27       Impact factor: 6.568

3.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

Authors:  Ryan B Corcoran; Hiromichi Ebi; Alexa B Turke; Erin M Coffee; Michiya Nishino; Alexandria P Cogdill; Ronald D Brown; Patricia Della Pelle; Dora Dias-Santagata; Kenneth E Hung; Keith T Flaherty; Adriano Piris; Jennifer A Wargo; Jeffrey Settleman; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2012-01-16       Impact factor: 39.397

4.  Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

Authors:  Keith C Bible; Vera J Suman; Julian R Molina; Robert C Smallridge; William J Maples; Michael E Menefee; Joseph Rubin; Kostandinos Sideras; John C Morris; Bryan McIver; Jill K Burton; Kevin P Webster; Carolyn Bieber; Anne M Traynor; Patrick J Flynn; Boon Cher Goh; Hui Tang; Susan Percy Ivy; Charles Erlichman
Journal:  Lancet Oncol       Date:  2010-09-17       Impact factor: 41.316

5.  Integrated genomic characterization of papillary thyroid carcinoma.

Authors: 
Journal:  Cell       Date:  2014-10-23       Impact factor: 41.582

6.  Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases.

Authors:  M M Sabra; J M Dominguez; R K Grewal; S M Larson; R A Ghossein; R M Tuttle; J A Fagin
Journal:  J Clin Endocrinol Metab       Date:  2013-03-26       Impact factor: 5.958

7.  Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.

Authors:  Marcia S Brose; Maria E Cabanillas; Ezra E W Cohen; Lori J Wirth; Todd Riehl; Huibin Yue; Steven I Sherman; Eric J Sherman
Journal:  Lancet Oncol       Date:  2016-07-23       Impact factor: 41.316

8.  Reciprocal epithelial:endothelial paracrine interactions during thyroid development govern follicular organization and C-cells differentiation.

Authors:  Anne-Christine Hick; Anne-Sophie Delmarcelle; Mahé Bouquet; Sabrina Klotz; Tamara Copetti; Celine Forez; Patrick Van Der Smissen; Pierre Sonveaux; Jean-François Collet; Olivier Feron; Pierre J Courtoy; Christophe E Pierreux
Journal:  Dev Biol       Date:  2013-05-21       Impact factor: 3.582

9.  RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.

Authors:  Rossella Elisei; Cristina Romei; Barbara Cosci; Laura Agate; Valeria Bottici; Eleonora Molinaro; Mariangela Sculli; Paolo Miccoli; Fulvio Basolo; Lucia Grasso; Furio Pacini; Aldo Pinchera
Journal:  J Clin Endocrinol Metab       Date:  2007-09-25       Impact factor: 5.958

10.  Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.

Authors:  Scott Kopetz; Jayesh Desai; Emily Chan; Joel Randolph Hecht; Peter J O'Dwyer; Dipen Maru; Van Morris; Filip Janku; Arvind Dasari; Woonbook Chung; Jean-Pierre J Issa; Peter Gibbs; Brian James; Garth Powis; Keith B Nolop; Suman Bhattacharya; Leonard Saltz
Journal:  J Clin Oncol       Date:  2015-10-12       Impact factor: 44.544
View more
  219 in total

Review 1.  2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer.

Authors:  Laura Fugazzola; Rossella Elisei; Dagmar Fuhrer; Barbara Jarzab; Sophie Leboulleux; Kate Newbold; Jan Smit
Journal:  Eur Thyroid J       Date:  2019-08-28

2.  Locally invasive thyroid cancer: options for a treatment.

Authors:  Nicola Avenia; Jacopo Vannucci; Massimo Monacelli; Andrea Polistena; Francesco Puma
Journal:  Updates Surg       Date:  2017-04-13

3.  Thyroid Cancer Brain Metastasis: Survival and Genomic Characteristics of a Large Tertiary Care Cohort.

Authors:  Joseph R Osborne; Jessica D Kondraciuk; Samuel L Rice; Xiaosun Zhou; Andrea Knezevic; Daniel E Spratt; Mona Sabra; Steven M Larson; Ravinder K Grewal
Journal:  Clin Nucl Med       Date:  2019-07       Impact factor: 7.794

4.  Microsatellite Instability Occurs in a Subset of Follicular Thyroid Cancers.

Authors:  Luke K Genutis; Jerneja Tomsic; Ralf A Bundschuh; Pamela L Brock; Michelle D Williams; Sameek Roychowdhury; Julie W Reeser; Wendy L Frankel; Mohammed Alsomali; Mark J Routbort; Russell R Broaddus; Paul E Wakely; John E Phay; Christopher J Walker; Albert de la Chapelle
Journal:  Thyroid       Date:  2019-03-27       Impact factor: 6.568

5.  miR-650 promotes motility of anaplastic thyroid cancer cells by targeting PPP2CA.

Authors:  Francesca Maria Orlandella; Raffaela Mariarosaria Mariniello; Paola Lucia Chiara Iervolino; Esther Imperlini; Annalisa Mandola; Anna Verde; Anna Elisa De Stefano; Katia Pane; Monica Franzese; Silvia Esposito; Fulvio Basolo; Stefania Orrù; Giuliana Salvatore
Journal:  Endocrine       Date:  2019-03-29       Impact factor: 3.633

Review 6.  Clinically Relevant Prognostic Parameters in Differentiated Thyroid Carcinoma.

Authors:  Tyler Janovitz; Justine A Barletta
Journal:  Endocr Pathol       Date:  2018-12       Impact factor: 3.943

7.  SEOM clinical guideline thyroid cancer (2019).

Authors:  E Gallardo; J Medina; J C Sánchez; A Viúdez; E Grande; I Porras; T Ramón Y Cajal; J Trigo; L Iglesias; J Capdevila
Journal:  Clin Transl Oncol       Date:  2020-01-31       Impact factor: 3.405

8.  Characterization of thyroid cancer driven by known and novel ALK fusions.

Authors:  Federica Panebianco; Alyaksandr V Nikitski; Marina N Nikiforova; Cihan Kaya; Linwah Yip; Vincenzo Condello; Abigail I Wald; Yuri E Nikiforov; Simion I Chiosea
Journal:  Endocr Relat Cancer       Date:  2019-11       Impact factor: 5.678

9.  Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers.

Authors:  Rebecca E Schweppe; Nikita Pozdeyev; Laura A Pike; Christopher Korch; Qiong Zhou; Sharon B Sams; Vibha Sharma; Umarani Pugazhenthi; Christopher Raeburn; Maria B Albuja-Cruz; Philip Reigan; Daniel V LaBarbera; Iñigo Landa; Jeffrey A Knauf; James A Fagin; Bryan R Haugen
Journal:  Mol Cancer Res       Date:  2019-02-07       Impact factor: 5.852

10.  Expression and clinicopathological role of miR146a in thyroid follicular carcinoma.

Authors:  Elisa Pignatti; Eleonora Vighi; Elisa Magnani; Elda Kara; Luca Roncati; Antonino Maiorana; Daniele Santi; Bruno Madeo; Katia Cioni; Cesare Carani; Vincenzo Rochira; Manuela Simoni; Giulia Brigante
Journal:  Endocrine       Date:  2019-01-30       Impact factor: 3.633
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.